Bibliographic Details
| Title: |
Novartis' Sandoz: Between Generics and Pharma |
| Description: |
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry? |
| Authors: |
Carin-Isabel Knoop, Krishna G. Palepu |
| Resource Type: |
eBook. |
| Categories: |
BUSINESS & ECONOMICS / General |
| Database: |
eBook Collection (EBSCOhost) |
